nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.542	1	CiPCiCtD
Sirolimus—FGF2—melanoma	0.214	0.877	CbGaD
Sirolimus—ABCB1—melanoma	0.03	0.123	CbGaD
Sirolimus—CYP3A4—Temozolomide—melanoma	0.0148	0.226	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.00952	0.145	CbGbCtD
Sirolimus—CYP3A7—Docetaxel—melanoma	0.00952	0.145	CbGbCtD
Sirolimus—ABCB1—Dactinomycin—melanoma	0.009	0.137	CbGbCtD
Sirolimus—CYP3A4—Vemurafenib—melanoma	0.00811	0.124	CbGbCtD
Sirolimus—CYP3A5—Docetaxel—melanoma	0.00714	0.109	CbGbCtD
Sirolimus—ABCB1—Docetaxel—melanoma	0.00465	0.0709	CbGbCtD
Sirolimus—CYP3A4—Docetaxel—melanoma	0.00278	0.0425	CbGbCtD
Sirolimus—MTOR—leg—melanoma	0.00223	0.134	CbGeAlD
Sirolimus—MTOR—hindlimb—melanoma	0.00199	0.119	CbGeAlD
Sirolimus—MTOR—appendage—melanoma	0.00171	0.102	CbGeAlD
Sirolimus—MTOR—blood vessel—melanoma	0.00095	0.057	CbGeAlD
Sirolimus—FGF2—eye—melanoma	0.000796	0.0478	CbGeAlD
Sirolimus—EIF4E—head—melanoma	0.000741	0.0445	CbGeAlD
Sirolimus—MTOR—neck—melanoma	0.000679	0.0408	CbGeAlD
Sirolimus—FGF2—mammalian vulva—melanoma	0.000632	0.038	CbGeAlD
Sirolimus—FKBP1A—neck—melanoma	0.000611	0.0367	CbGeAlD
Sirolimus—MTOR—eye—melanoma	0.000505	0.0304	CbGeAlD
Sirolimus—MTOR—retina—melanoma	0.000501	0.0301	CbGeAlD
Sirolimus—FKBP1A—eye—melanoma	0.000454	0.0273	CbGeAlD
Sirolimus—FKBP1A—retina—melanoma	0.00045	0.0271	CbGeAlD
Sirolimus—MTOR—skin of body—melanoma	0.00044	0.0264	CbGeAlD
Sirolimus—MTOR—mammalian vulva—melanoma	0.000401	0.0241	CbGeAlD
Sirolimus—FKBP1A—skin of body—melanoma	0.000395	0.0238	CbGeAlD
Sirolimus—SLC47A1—eye—melanoma	0.000391	0.0235	CbGeAlD
Sirolimus—FKBP1A—mammalian vulva—melanoma	0.000361	0.0217	CbGeAlD
Sirolimus—FGF2—lymph node—melanoma	0.000317	0.019	CbGeAlD
Sirolimus—SLC47A1—mammalian vulva—melanoma	0.00031	0.0186	CbGeAlD
Sirolimus—MTOR—head—melanoma	0.000287	0.0172	CbGeAlD
Sirolimus—FKBP1A—head—melanoma	0.000258	0.0155	CbGeAlD
Sirolimus—SLC47A1—head—melanoma	0.000222	0.0133	CbGeAlD
Sirolimus—MTOR—lymph node—melanoma	0.000201	0.0121	CbGeAlD
Sirolimus—ABCB1—blood vessel—melanoma	0.000198	0.0119	CbGeAlD
Sirolimus—FKBP1A—lymph node—melanoma	0.000181	0.0109	CbGeAlD
Sirolimus—SLC47A1—lymph node—melanoma	0.000155	0.00933	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—melanoma	0.000112	0.357	CrCbGaD
Sirolimus—ABCB1—retina—melanoma	0.000104	0.00626	CbGeAlD
Sirolimus—Tacrolimus—ALB—melanoma	0.000103	0.329	CrCbGaD
Sirolimus—Tacrolimus—ABCB1—melanoma	9.82e-05	0.314	CrCbGaD
Sirolimus—Asthenia—Vemurafenib—melanoma	8.37e-05	0.00146	CcSEcCtD
Sirolimus—Visual impairment—Carmustine—melanoma	8.37e-05	0.00146	CcSEcCtD
Sirolimus—Hallucination—Temozolomide—melanoma	8.35e-05	0.00145	CcSEcCtD
Sirolimus—Hypoaesthesia—Temozolomide—melanoma	8.35e-05	0.00145	CcSEcCtD
Sirolimus—ABCB1—mammalian vulva—melanoma	8.34e-05	0.00501	CbGeAlD
Sirolimus—Pharyngitis—Temozolomide—melanoma	8.33e-05	0.00145	CcSEcCtD
Sirolimus—Chills—Dactinomycin—melanoma	8.33e-05	0.00145	CcSEcCtD
Sirolimus—Urinary tract disorder—Temozolomide—melanoma	8.29e-05	0.00144	CcSEcCtD
Sirolimus—Oedema peripheral—Temozolomide—melanoma	8.27e-05	0.00144	CcSEcCtD
Sirolimus—Pruritus—Vemurafenib—melanoma	8.25e-05	0.00144	CcSEcCtD
Sirolimus—Connective tissue disorder—Temozolomide—melanoma	8.25e-05	0.00144	CcSEcCtD
Sirolimus—Urethral disorder—Temozolomide—melanoma	8.23e-05	0.00143	CcSEcCtD
Sirolimus—Hyponatraemia—Docetaxel—melanoma	8.1e-05	0.00141	CcSEcCtD
Sirolimus—Visual impairment—Temozolomide—melanoma	8.09e-05	0.00141	CcSEcCtD
Sirolimus—Ill-defined disorder—Bleomycin—melanoma	8.04e-05	0.0014	CcSEcCtD
Sirolimus—Anaemia—Bleomycin—melanoma	8.01e-05	0.00139	CcSEcCtD
Sirolimus—Diarrhoea—Vemurafenib—melanoma	7.98e-05	0.00139	CcSEcCtD
Sirolimus—Tinnitus—Temozolomide—melanoma	7.83e-05	0.00136	CcSEcCtD
Sirolimus—Malaise—Bleomycin—melanoma	7.81e-05	0.00136	CcSEcCtD
Sirolimus—Cardiac disorder—Temozolomide—melanoma	7.79e-05	0.00136	CcSEcCtD
Sirolimus—Leukopenia—Bleomycin—melanoma	7.75e-05	0.00135	CcSEcCtD
Sirolimus—Dizziness—Vemurafenib—melanoma	7.72e-05	0.00134	CcSEcCtD
Sirolimus—Angiopathy—Temozolomide—melanoma	7.61e-05	0.00133	CcSEcCtD
Sirolimus—Immune system disorder—Temozolomide—melanoma	7.58e-05	0.00132	CcSEcCtD
Sirolimus—Mediastinal disorder—Temozolomide—melanoma	7.56e-05	0.00132	CcSEcCtD
Sirolimus—Malnutrition—Carmustine—melanoma	7.56e-05	0.00132	CcSEcCtD
Sirolimus—Cough—Bleomycin—melanoma	7.56e-05	0.00132	CcSEcCtD
Sirolimus—Chills—Temozolomide—melanoma	7.53e-05	0.00131	CcSEcCtD
Sirolimus—Dehydration—Docetaxel—melanoma	7.5e-05	0.00131	CcSEcCtD
Sirolimus—Ill-defined disorder—Dactinomycin—melanoma	7.49e-05	0.00131	CcSEcCtD
Sirolimus—Anaemia—Dactinomycin—melanoma	7.47e-05	0.0013	CcSEcCtD
Sirolimus—Liver function test abnormal—Docetaxel—melanoma	7.45e-05	0.0013	CcSEcCtD
Sirolimus—Vomiting—Vemurafenib—melanoma	7.42e-05	0.00129	CcSEcCtD
Sirolimus—Chest pain—Bleomycin—melanoma	7.37e-05	0.00128	CcSEcCtD
Sirolimus—Myalgia—Bleomycin—melanoma	7.37e-05	0.00128	CcSEcCtD
Sirolimus—Orthostatic hypotension—Docetaxel—melanoma	7.37e-05	0.00128	CcSEcCtD
Sirolimus—Rash—Vemurafenib—melanoma	7.36e-05	0.00128	CcSEcCtD
Sirolimus—Dermatitis—Vemurafenib—melanoma	7.35e-05	0.00128	CcSEcCtD
Sirolimus—Back pain—Carmustine—melanoma	7.31e-05	0.00127	CcSEcCtD
Sirolimus—Headache—Vemurafenib—melanoma	7.31e-05	0.00127	CcSEcCtD
Sirolimus—Malnutrition—Temozolomide—melanoma	7.31e-05	0.00127	CcSEcCtD
Sirolimus—Breast disorder—Docetaxel—melanoma	7.29e-05	0.00127	CcSEcCtD
Sirolimus—Discomfort—Bleomycin—melanoma	7.29e-05	0.00127	CcSEcCtD
Sirolimus—Malaise—Dactinomycin—melanoma	7.28e-05	0.00127	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Docetaxel—melanoma	7.27e-05	0.00127	CcSEcCtD
Sirolimus—Leukopenia—Dactinomycin—melanoma	7.23e-05	0.00126	CcSEcCtD
Sirolimus—Confusional state—Bleomycin—melanoma	7.13e-05	0.00124	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Docetaxel—melanoma	7.12e-05	0.00124	CcSEcCtD
Sirolimus—Tremor—Carmustine—melanoma	7.08e-05	0.00123	CcSEcCtD
Sirolimus—Oedema—Bleomycin—melanoma	7.07e-05	0.00123	CcSEcCtD
Sirolimus—Anaphylactic shock—Bleomycin—melanoma	7.07e-05	0.00123	CcSEcCtD
Sirolimus—Back pain—Temozolomide—melanoma	7.07e-05	0.00123	CcSEcCtD
Sirolimus—Infection—Bleomycin—melanoma	7.02e-05	0.00122	CcSEcCtD
Sirolimus—Anaemia—Carmustine—melanoma	6.99e-05	0.00122	CcSEcCtD
Sirolimus—Dysphagia—Docetaxel—melanoma	6.97e-05	0.00121	CcSEcCtD
Sirolimus—Agitation—Carmustine—melanoma	6.95e-05	0.00121	CcSEcCtD
Sirolimus—Nausea—Vemurafenib—melanoma	6.93e-05	0.00121	CcSEcCtD
Sirolimus—Thrombocytopenia—Bleomycin—melanoma	6.92e-05	0.00121	CcSEcCtD
Sirolimus—Myalgia—Dactinomycin—melanoma	6.88e-05	0.0012	CcSEcCtD
Sirolimus—Tremor—Temozolomide—melanoma	6.85e-05	0.00119	CcSEcCtD
Sirolimus—Discomfort—Dactinomycin—melanoma	6.79e-05	0.00118	CcSEcCtD
Sirolimus—Ill-defined disorder—Temozolomide—melanoma	6.78e-05	0.00118	CcSEcCtD
Sirolimus—Leukopenia—Carmustine—melanoma	6.77e-05	0.00118	CcSEcCtD
Sirolimus—Anaemia—Temozolomide—melanoma	6.75e-05	0.00118	CcSEcCtD
Sirolimus—Anorexia—Bleomycin—melanoma	6.74e-05	0.00117	CcSEcCtD
Sirolimus—Agitation—Temozolomide—melanoma	6.71e-05	0.00117	CcSEcCtD
Sirolimus—Angioedema—Temozolomide—melanoma	6.68e-05	0.00116	CcSEcCtD
Sirolimus—Pancytopenia—Docetaxel—melanoma	6.62e-05	0.00115	CcSEcCtD
Sirolimus—Hypotension—Bleomycin—melanoma	6.61e-05	0.00115	CcSEcCtD
Sirolimus—Oedema—Dactinomycin—melanoma	6.59e-05	0.00115	CcSEcCtD
Sirolimus—Malaise—Temozolomide—melanoma	6.59e-05	0.00115	CcSEcCtD
Sirolimus—Infection—Dactinomycin—melanoma	6.55e-05	0.00114	CcSEcCtD
Sirolimus—Leukopenia—Temozolomide—melanoma	6.54e-05	0.00114	CcSEcCtD
Sirolimus—Hypertension—Carmustine—melanoma	6.53e-05	0.00114	CcSEcCtD
Sirolimus—Neutropenia—Docetaxel—melanoma	6.52e-05	0.00114	CcSEcCtD
Sirolimus—Palpitations—Temozolomide—melanoma	6.46e-05	0.00112	CcSEcCtD
Sirolimus—Thrombocytopenia—Dactinomycin—melanoma	6.45e-05	0.00112	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Bleomycin—melanoma	6.44e-05	0.00112	CcSEcCtD
Sirolimus—Chest pain—Carmustine—melanoma	6.44e-05	0.00112	CcSEcCtD
Sirolimus—Myalgia—Carmustine—melanoma	6.44e-05	0.00112	CcSEcCtD
Sirolimus—Anxiety—Carmustine—melanoma	6.41e-05	0.00112	CcSEcCtD
Sirolimus—Cough—Temozolomide—melanoma	6.38e-05	0.00111	CcSEcCtD
Sirolimus—Paraesthesia—Bleomycin—melanoma	6.35e-05	0.00111	CcSEcCtD
Sirolimus—Weight increased—Docetaxel—melanoma	6.35e-05	0.00111	CcSEcCtD
Sirolimus—Weight decreased—Docetaxel—melanoma	6.31e-05	0.0011	CcSEcCtD
Sirolimus—Hypertension—Temozolomide—melanoma	6.31e-05	0.0011	CcSEcCtD
Sirolimus—Dyspnoea—Bleomycin—melanoma	6.3e-05	0.0011	CcSEcCtD
Sirolimus—Anorexia—Dactinomycin—melanoma	6.28e-05	0.00109	CcSEcCtD
Sirolimus—Pneumonia—Docetaxel—melanoma	6.25e-05	0.00109	CcSEcCtD
Sirolimus—Confusional state—Carmustine—melanoma	6.22e-05	0.00108	CcSEcCtD
Sirolimus—Arthralgia—Temozolomide—melanoma	6.22e-05	0.00108	CcSEcCtD
Sirolimus—Myalgia—Temozolomide—melanoma	6.22e-05	0.00108	CcSEcCtD
Sirolimus—Infestation NOS—Docetaxel—melanoma	6.22e-05	0.00108	CcSEcCtD
Sirolimus—Infestation—Docetaxel—melanoma	6.22e-05	0.00108	CcSEcCtD
Sirolimus—Anxiety—Temozolomide—melanoma	6.2e-05	0.00108	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	6.18e-05	0.00108	CcSEcCtD
Sirolimus—Oedema—Carmustine—melanoma	6.17e-05	0.00107	CcSEcCtD
Sirolimus—Discomfort—Temozolomide—melanoma	6.15e-05	0.00107	CcSEcCtD
Sirolimus—Decreased appetite—Bleomycin—melanoma	6.14e-05	0.00107	CcSEcCtD
Sirolimus—Infection—Carmustine—melanoma	6.13e-05	0.00107	CcSEcCtD
Sirolimus—Neuropathy peripheral—Docetaxel—melanoma	6.09e-05	0.00106	CcSEcCtD
Sirolimus—Stomatitis—Docetaxel—melanoma	6.06e-05	0.00106	CcSEcCtD
Sirolimus—Pain—Bleomycin—melanoma	6.04e-05	0.00105	CcSEcCtD
Sirolimus—Conjunctivitis—Docetaxel—melanoma	6.04e-05	0.00105	CcSEcCtD
Sirolimus—Thrombocytopenia—Carmustine—melanoma	6.04e-05	0.00105	CcSEcCtD
Sirolimus—Tachycardia—Carmustine—melanoma	6.02e-05	0.00105	CcSEcCtD
Sirolimus—Confusional state—Temozolomide—melanoma	6.01e-05	0.00105	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Dactinomycin—melanoma	6.01e-05	0.00105	CcSEcCtD
Sirolimus—ABCB1—head—melanoma	5.97e-05	0.00359	CbGeAlD
Sirolimus—Oedema—Temozolomide—melanoma	5.96e-05	0.00104	CcSEcCtD
Sirolimus—Anaphylactic shock—Temozolomide—melanoma	5.96e-05	0.00104	CcSEcCtD
Sirolimus—Infection—Temozolomide—melanoma	5.92e-05	0.00103	CcSEcCtD
Sirolimus—Anorexia—Carmustine—melanoma	5.88e-05	0.00102	CcSEcCtD
Sirolimus—Hepatobiliary disease—Docetaxel—melanoma	5.88e-05	0.00102	CcSEcCtD
Sirolimus—Epistaxis—Docetaxel—melanoma	5.86e-05	0.00102	CcSEcCtD
Sirolimus—Nervous system disorder—Temozolomide—melanoma	5.85e-05	0.00102	CcSEcCtD
Sirolimus—Thrombocytopenia—Temozolomide—melanoma	5.84e-05	0.00102	CcSEcCtD
Sirolimus—Feeling abnormal—Bleomycin—melanoma	5.83e-05	0.00101	CcSEcCtD
Sirolimus—Skin disorder—Temozolomide—melanoma	5.79e-05	0.00101	CcSEcCtD
Sirolimus—Hypotension—Carmustine—melanoma	5.77e-05	0.001	CcSEcCtD
Sirolimus—Hyperhidrosis—Temozolomide—melanoma	5.76e-05	0.001	CcSEcCtD
Sirolimus—Decreased appetite—Dactinomycin—melanoma	5.73e-05	0.000998	CcSEcCtD
Sirolimus—Anorexia—Temozolomide—melanoma	5.68e-05	0.00099	CcSEcCtD
Sirolimus—Pain—Dactinomycin—melanoma	5.64e-05	0.000982	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Carmustine—melanoma	5.62e-05	0.000979	CcSEcCtD
Sirolimus—Haemoglobin—Docetaxel—melanoma	5.61e-05	0.000977	CcSEcCtD
Sirolimus—Rhinitis—Docetaxel—melanoma	5.6e-05	0.000974	CcSEcCtD
Sirolimus—Body temperature increased—Bleomycin—melanoma	5.59e-05	0.000973	CcSEcCtD
Sirolimus—Haemorrhage—Docetaxel—melanoma	5.58e-05	0.000972	CcSEcCtD
Sirolimus—Insomnia—Carmustine—melanoma	5.58e-05	0.000972	CcSEcCtD
Sirolimus—Hypoaesthesia—Docetaxel—melanoma	5.55e-05	0.000967	CcSEcCtD
Sirolimus—Paraesthesia—Carmustine—melanoma	5.54e-05	0.000965	CcSEcCtD
Sirolimus—Pharyngitis—Docetaxel—melanoma	5.54e-05	0.000965	CcSEcCtD
Sirolimus—Urinary tract disorder—Docetaxel—melanoma	5.51e-05	0.00096	CcSEcCtD
Sirolimus—Dyspnoea—Carmustine—melanoma	5.5e-05	0.000958	CcSEcCtD
Sirolimus—Oedema peripheral—Docetaxel—melanoma	5.5e-05	0.000957	CcSEcCtD
Sirolimus—Somnolence—Carmustine—melanoma	5.49e-05	0.000955	CcSEcCtD
Sirolimus—Connective tissue disorder—Docetaxel—melanoma	5.48e-05	0.000955	CcSEcCtD
Sirolimus—Urethral disorder—Docetaxel—melanoma	5.47e-05	0.000953	CcSEcCtD
Sirolimus—Feeling abnormal—Dactinomycin—melanoma	5.43e-05	0.000946	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Temozolomide—melanoma	5.43e-05	0.000946	CcSEcCtD
Sirolimus—Insomnia—Temozolomide—melanoma	5.39e-05	0.000939	CcSEcCtD
Sirolimus—Gastrointestinal pain—Dactinomycin—melanoma	5.39e-05	0.000939	CcSEcCtD
Sirolimus—Visual impairment—Docetaxel—melanoma	5.38e-05	0.000937	CcSEcCtD
Sirolimus—Decreased appetite—Carmustine—melanoma	5.36e-05	0.000934	CcSEcCtD
Sirolimus—Paraesthesia—Temozolomide—melanoma	5.35e-05	0.000932	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Carmustine—melanoma	5.33e-05	0.000928	CcSEcCtD
Sirolimus—Dyspnoea—Temozolomide—melanoma	5.32e-05	0.000926	CcSEcCtD
Sirolimus—Somnolence—Temozolomide—melanoma	5.3e-05	0.000923	CcSEcCtD
Sirolimus—Pain—Carmustine—melanoma	5.28e-05	0.000919	CcSEcCtD
Sirolimus—Constipation—Carmustine—melanoma	5.28e-05	0.000919	CcSEcCtD
Sirolimus—Dyspepsia—Temozolomide—melanoma	5.25e-05	0.000914	CcSEcCtD
Sirolimus—Abdominal pain—Dactinomycin—melanoma	5.21e-05	0.000907	CcSEcCtD
Sirolimus—Body temperature increased—Dactinomycin—melanoma	5.21e-05	0.000907	CcSEcCtD
Sirolimus—Hypersensitivity—Bleomycin—melanoma	5.21e-05	0.000907	CcSEcCtD
Sirolimus—Decreased appetite—Temozolomide—melanoma	5.18e-05	0.000903	CcSEcCtD
Sirolimus—Cardiac disorder—Docetaxel—melanoma	5.18e-05	0.000902	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Temozolomide—melanoma	5.15e-05	0.000896	CcSEcCtD
Sirolimus—Pain—Temozolomide—melanoma	5.1e-05	0.000888	CcSEcCtD
Sirolimus—Constipation—Temozolomide—melanoma	5.1e-05	0.000888	CcSEcCtD
Sirolimus—Feeling abnormal—Carmustine—melanoma	5.08e-05	0.000885	CcSEcCtD
Sirolimus—Asthenia—Bleomycin—melanoma	5.07e-05	0.000883	CcSEcCtD
Sirolimus—Angiopathy—Docetaxel—melanoma	5.06e-05	0.000882	CcSEcCtD
Sirolimus—Gastrointestinal pain—Carmustine—melanoma	5.05e-05	0.000879	CcSEcCtD
Sirolimus—Immune system disorder—Docetaxel—melanoma	5.04e-05	0.000878	CcSEcCtD
Sirolimus—Mediastinal disorder—Docetaxel—melanoma	5.03e-05	0.000876	CcSEcCtD
Sirolimus—Chills—Docetaxel—melanoma	5.01e-05	0.000872	CcSEcCtD
Sirolimus—Pruritus—Bleomycin—melanoma	5e-05	0.000871	CcSEcCtD
Sirolimus—Feeling abnormal—Temozolomide—melanoma	4.91e-05	0.000856	CcSEcCtD
Sirolimus—Body temperature increased—Carmustine—melanoma	4.88e-05	0.000849	CcSEcCtD
Sirolimus—Abdominal pain—Carmustine—melanoma	4.88e-05	0.000849	CcSEcCtD
Sirolimus—Gastrointestinal pain—Temozolomide—melanoma	4.88e-05	0.000849	CcSEcCtD
Sirolimus—Malnutrition—Docetaxel—melanoma	4.86e-05	0.000846	CcSEcCtD
Sirolimus—Hypersensitivity—Dactinomycin—melanoma	4.86e-05	0.000846	CcSEcCtD
Sirolimus—Asthenia—Dactinomycin—melanoma	4.73e-05	0.000824	CcSEcCtD
Sirolimus—Abdominal pain—Temozolomide—melanoma	4.71e-05	0.000821	CcSEcCtD
Sirolimus—Body temperature increased—Temozolomide—melanoma	4.71e-05	0.000821	CcSEcCtD
Sirolimus—Back pain—Docetaxel—melanoma	4.7e-05	0.000818	CcSEcCtD
Sirolimus—Muscle spasms—Docetaxel—melanoma	4.67e-05	0.000813	CcSEcCtD
Sirolimus—Hypersensitivity—Carmustine—melanoma	4.55e-05	0.000792	CcSEcCtD
Sirolimus—Diarrhoea—Dactinomycin—melanoma	4.51e-05	0.000785	CcSEcCtD
Sirolimus—Vomiting—Bleomycin—melanoma	4.49e-05	0.000783	CcSEcCtD
Sirolimus—Anaemia—Docetaxel—melanoma	4.49e-05	0.000782	CcSEcCtD
Sirolimus—Rash—Bleomycin—melanoma	4.46e-05	0.000776	CcSEcCtD
Sirolimus—Dermatitis—Bleomycin—melanoma	4.45e-05	0.000775	CcSEcCtD
Sirolimus—Asthenia—Carmustine—melanoma	4.43e-05	0.000771	CcSEcCtD
Sirolimus—Hypersensitivity—Temozolomide—melanoma	4.39e-05	0.000765	CcSEcCtD
Sirolimus—Syncope—Docetaxel—melanoma	4.36e-05	0.000759	CcSEcCtD
Sirolimus—Leukopenia—Docetaxel—melanoma	4.35e-05	0.000757	CcSEcCtD
Sirolimus—Palpitations—Docetaxel—melanoma	4.29e-05	0.000748	CcSEcCtD
Sirolimus—Asthenia—Temozolomide—melanoma	4.28e-05	0.000745	CcSEcCtD
Sirolimus—Loss of consciousness—Docetaxel—melanoma	4.27e-05	0.000744	CcSEcCtD
Sirolimus—Cough—Docetaxel—melanoma	4.24e-05	0.000738	CcSEcCtD
Sirolimus—Diarrhoea—Carmustine—melanoma	4.22e-05	0.000735	CcSEcCtD
Sirolimus—Pruritus—Temozolomide—melanoma	4.22e-05	0.000735	CcSEcCtD
Sirolimus—Nausea—Bleomycin—melanoma	4.2e-05	0.000731	CcSEcCtD
Sirolimus—Hypertension—Docetaxel—melanoma	4.19e-05	0.00073	CcSEcCtD
Sirolimus—Vomiting—Dactinomycin—melanoma	4.19e-05	0.00073	CcSEcCtD
Sirolimus—ABCB1—lymph node—melanoma	4.18e-05	0.00251	CbGeAlD
Sirolimus—Rash—Dactinomycin—melanoma	4.16e-05	0.000724	CcSEcCtD
Sirolimus—Myalgia—Docetaxel—melanoma	4.14e-05	0.00072	CcSEcCtD
Sirolimus—Arthralgia—Docetaxel—melanoma	4.14e-05	0.00072	CcSEcCtD
Sirolimus—Chest pain—Docetaxel—melanoma	4.14e-05	0.00072	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	4.11e-05	0.000715	CcSEcCtD
Sirolimus—Dizziness—Carmustine—melanoma	4.08e-05	0.00071	CcSEcCtD
Sirolimus—Diarrhoea—Temozolomide—melanoma	4.08e-05	0.00071	CcSEcCtD
Sirolimus—Confusional state—Docetaxel—melanoma	4e-05	0.000696	CcSEcCtD
Sirolimus—Anaphylactic shock—Docetaxel—melanoma	3.97e-05	0.00069	CcSEcCtD
Sirolimus—Oedema—Docetaxel—melanoma	3.97e-05	0.00069	CcSEcCtD
Sirolimus—Dizziness—Temozolomide—melanoma	3.94e-05	0.000687	CcSEcCtD
Sirolimus—Infection—Docetaxel—melanoma	3.94e-05	0.000686	CcSEcCtD
Sirolimus—Vomiting—Carmustine—melanoma	3.92e-05	0.000683	CcSEcCtD
Sirolimus—Nausea—Dactinomycin—melanoma	3.92e-05	0.000682	CcSEcCtD
Sirolimus—Shock—Docetaxel—melanoma	3.9e-05	0.000679	CcSEcCtD
Sirolimus—Rash—Carmustine—melanoma	3.89e-05	0.000677	CcSEcCtD
Sirolimus—Nervous system disorder—Docetaxel—melanoma	3.89e-05	0.000677	CcSEcCtD
Sirolimus—Dermatitis—Carmustine—melanoma	3.89e-05	0.000677	CcSEcCtD
Sirolimus—Thrombocytopenia—Docetaxel—melanoma	3.88e-05	0.000676	CcSEcCtD
Sirolimus—Tachycardia—Docetaxel—melanoma	3.87e-05	0.000674	CcSEcCtD
Sirolimus—Headache—Carmustine—melanoma	3.87e-05	0.000673	CcSEcCtD
Sirolimus—Skin disorder—Docetaxel—melanoma	3.85e-05	0.000671	CcSEcCtD
Sirolimus—Vomiting—Temozolomide—melanoma	3.79e-05	0.00066	CcSEcCtD
Sirolimus—Anorexia—Docetaxel—melanoma	3.78e-05	0.000658	CcSEcCtD
Sirolimus—Rash—Temozolomide—melanoma	3.76e-05	0.000655	CcSEcCtD
Sirolimus—Dermatitis—Temozolomide—melanoma	3.76e-05	0.000654	CcSEcCtD
Sirolimus—Headache—Temozolomide—melanoma	3.74e-05	0.00065	CcSEcCtD
Sirolimus—Hypotension—Docetaxel—melanoma	3.71e-05	0.000645	CcSEcCtD
Sirolimus—Nausea—Carmustine—melanoma	3.67e-05	0.000638	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Docetaxel—melanoma	3.61e-05	0.000629	CcSEcCtD
Sirolimus—Insomnia—Docetaxel—melanoma	3.59e-05	0.000625	CcSEcCtD
Sirolimus—Paraesthesia—Docetaxel—melanoma	3.56e-05	0.00062	CcSEcCtD
Sirolimus—Nausea—Temozolomide—melanoma	3.54e-05	0.000617	CcSEcCtD
Sirolimus—Dyspnoea—Docetaxel—melanoma	3.54e-05	0.000616	CcSEcCtD
Sirolimus—Somnolence—Docetaxel—melanoma	3.53e-05	0.000614	CcSEcCtD
Sirolimus—Dyspepsia—Docetaxel—melanoma	3.49e-05	0.000608	CcSEcCtD
Sirolimus—Decreased appetite—Docetaxel—melanoma	3.45e-05	0.0006	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Docetaxel—melanoma	3.42e-05	0.000596	CcSEcCtD
Sirolimus—Pain—Docetaxel—melanoma	3.39e-05	0.00059	CcSEcCtD
Sirolimus—Constipation—Docetaxel—melanoma	3.39e-05	0.00059	CcSEcCtD
Sirolimus—Feeling abnormal—Docetaxel—melanoma	3.27e-05	0.000569	CcSEcCtD
Sirolimus—Gastrointestinal pain—Docetaxel—melanoma	3.24e-05	0.000565	CcSEcCtD
Sirolimus—Abdominal pain—Docetaxel—melanoma	3.13e-05	0.000546	CcSEcCtD
Sirolimus—Body temperature increased—Docetaxel—melanoma	3.13e-05	0.000546	CcSEcCtD
Sirolimus—Hypersensitivity—Docetaxel—melanoma	2.92e-05	0.000509	CcSEcCtD
Sirolimus—Asthenia—Docetaxel—melanoma	2.85e-05	0.000495	CcSEcCtD
Sirolimus—Pruritus—Docetaxel—melanoma	2.81e-05	0.000489	CcSEcCtD
Sirolimus—Diarrhoea—Docetaxel—melanoma	2.71e-05	0.000472	CcSEcCtD
Sirolimus—Dizziness—Docetaxel—melanoma	2.62e-05	0.000457	CcSEcCtD
Sirolimus—Vomiting—Docetaxel—melanoma	2.52e-05	0.000439	CcSEcCtD
Sirolimus—Rash—Docetaxel—melanoma	2.5e-05	0.000435	CcSEcCtD
Sirolimus—Dermatitis—Docetaxel—melanoma	2.5e-05	0.000435	CcSEcCtD
Sirolimus—Headache—Docetaxel—melanoma	2.48e-05	0.000433	CcSEcCtD
Sirolimus—Nausea—Docetaxel—melanoma	2.36e-05	0.00041	CcSEcCtD
Sirolimus—ABCB1—Metabolism—VCAN—melanoma	1.99e-06	2.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—melanoma	1.99e-06	2.69e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MDM2—melanoma	1.99e-06	2.69e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—melanoma	1.97e-06	2.67e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PRKCA—melanoma	1.96e-06	2.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGF2—melanoma	1.96e-06	2.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—melanoma	1.96e-06	2.65e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNAQ—melanoma	1.95e-06	2.65e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CD44—melanoma	1.95e-06	2.65e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ERCC2—melanoma	1.95e-06	2.64e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAP2K1—melanoma	1.94e-06	2.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—melanoma	1.94e-06	2.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—melanoma	1.93e-06	2.62e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—melanoma	1.93e-06	2.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CB—melanoma	1.93e-06	2.62e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CD—melanoma	1.93e-06	2.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—melanoma	1.93e-06	2.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RAC1—melanoma	1.93e-06	2.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—melanoma	1.93e-06	2.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1A—melanoma	1.92e-06	2.6e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK3—melanoma	1.92e-06	2.6e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—melanoma	1.92e-06	2.6e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NFKB1—melanoma	1.91e-06	2.59e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1B1—melanoma	1.87e-06	2.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—melanoma	1.87e-06	2.53e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—melanoma	1.86e-06	2.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—melanoma	1.85e-06	2.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HIF1A—melanoma	1.85e-06	2.51e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—melanoma	1.85e-06	2.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MDM2—melanoma	1.83e-06	2.48e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK1—melanoma	1.83e-06	2.48e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—melanoma	1.83e-06	2.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1B—melanoma	1.81e-06	2.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—melanoma	1.81e-06	2.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—melanoma	1.8e-06	2.43e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—melanoma	1.79e-06	2.42e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—melanoma	1.79e-06	2.42e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—melanoma	1.79e-06	2.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CB—melanoma	1.78e-06	2.42e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PHGDH—melanoma	1.78e-06	2.42e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LUM—melanoma	1.78e-06	2.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—melanoma	1.78e-06	2.41e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK3—melanoma	1.77e-06	2.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—melanoma	1.77e-06	2.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—melanoma	1.77e-06	2.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—melanoma	1.77e-06	2.39e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.76e-06	2.38e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HPSE—melanoma	1.75e-06	2.37e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—melanoma	1.73e-06	2.35e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MDM2—melanoma	1.73e-06	2.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—melanoma	1.73e-06	2.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—melanoma	1.73e-06	2.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	1.72e-06	2.33e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CUBN—melanoma	1.72e-06	2.33e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—melanoma	1.72e-06	2.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—melanoma	1.71e-06	2.32e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—melanoma	1.71e-06	2.32e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—melanoma	1.71e-06	2.32e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—melanoma	1.71e-06	2.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—melanoma	1.71e-06	2.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FN1—melanoma	1.7e-06	2.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK1—melanoma	1.69e-06	2.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—melanoma	1.69e-06	2.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CB—melanoma	1.68e-06	2.28e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP17A1—melanoma	1.68e-06	2.27e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CG—melanoma	1.68e-06	2.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1B—melanoma	1.67e-06	2.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—melanoma	1.67e-06	2.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—melanoma	1.67e-06	2.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH1—melanoma	1.67e-06	2.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NFKB1—melanoma	1.66e-06	2.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SDHD—melanoma	1.66e-06	2.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CSPG4—melanoma	1.66e-06	2.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BSG—melanoma	1.66e-06	2.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—melanoma	1.65e-06	2.24e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK3—melanoma	1.64e-06	2.22e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—melanoma	1.63e-06	2.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CD80—melanoma	1.63e-06	2.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—melanoma	1.63e-06	2.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CG—melanoma	1.63e-06	2.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—melanoma	1.63e-06	2.21e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—melanoma	1.62e-06	2.19e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—melanoma	1.62e-06	2.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGF—melanoma	1.61e-06	2.18e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPAM—melanoma	1.61e-06	2.17e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—melanoma	1.59e-06	2.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—melanoma	1.59e-06	2.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—melanoma	1.59e-06	2.15e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNA11—melanoma	1.59e-06	2.15e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—melanoma	1.59e-06	2.15e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—melanoma	1.58e-06	2.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1B—melanoma	1.58e-06	2.14e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—melanoma	1.58e-06	2.14e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK1—melanoma	1.56e-06	2.11e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—melanoma	1.56e-06	2.11e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	1.55e-06	2.11e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—FASN—melanoma	1.55e-06	2.1e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—melanoma	1.55e-06	2.1e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—melanoma	1.55e-06	2.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—melanoma	1.54e-06	2.09e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—melanoma	1.54e-06	2.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—melanoma	1.54e-06	2.09e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CG—melanoma	1.54e-06	2.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—melanoma	1.53e-06	2.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC5A5—melanoma	1.53e-06	2.07e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—melanoma	1.51e-06	2.04e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—melanoma	1.51e-06	2.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—melanoma	1.49e-06	2.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1—melanoma	1.49e-06	2.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—melanoma	1.49e-06	2.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—melanoma	1.49e-06	2.02e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—melanoma	1.48e-06	2.01e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNAQ—melanoma	1.47e-06	2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CD44—melanoma	1.47e-06	2e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CD—melanoma	1.47e-06	2e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—melanoma	1.47e-06	2e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—melanoma	1.47e-06	1.99e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—melanoma	1.47e-06	1.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—melanoma	1.46e-06	1.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—melanoma	1.46e-06	1.97e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—melanoma	1.45e-06	1.97e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—melanoma	1.45e-06	1.97e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NFKB1—melanoma	1.45e-06	1.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAP2K1—melanoma	1.44e-06	1.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CD—melanoma	1.43e-06	1.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK3—melanoma	1.43e-06	1.93e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PRKCA—melanoma	1.42e-06	1.92e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1B1—melanoma	1.41e-06	1.91e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ERCC2—melanoma	1.41e-06	1.91e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—melanoma	1.41e-06	1.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—melanoma	1.38e-06	1.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—melanoma	1.37e-06	1.86e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGF2—melanoma	1.37e-06	1.86e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLA2G6—melanoma	1.37e-06	1.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK1—melanoma	1.36e-06	1.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—melanoma	1.36e-06	1.84e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—melanoma	1.36e-06	1.84e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—melanoma	1.35e-06	1.83e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CD—melanoma	1.35e-06	1.83e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—melanoma	1.34e-06	1.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK3—melanoma	1.32e-06	1.78e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—melanoma	1.31e-06	1.78e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—melanoma	1.31e-06	1.77e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—melanoma	1.3e-06	1.76e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—melanoma	1.3e-06	1.76e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—melanoma	1.3e-06	1.76e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—melanoma	1.3e-06	1.76e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CB—melanoma	1.28e-06	1.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MDM2—melanoma	1.28e-06	1.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—melanoma	1.28e-06	1.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—melanoma	1.28e-06	1.73e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—melanoma	1.27e-06	1.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—melanoma	1.27e-06	1.71e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK1—melanoma	1.25e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—melanoma	1.25e-06	1.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—melanoma	1.25e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CB—melanoma	1.25e-06	1.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK3—melanoma	1.24e-06	1.68e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—VCAN—melanoma	1.23e-06	1.66e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—melanoma	1.21e-06	1.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—melanoma	1.2e-06	1.63e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—melanoma	1.2e-06	1.62e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—melanoma	1.2e-06	1.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—melanoma	1.18e-06	1.6e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK1—melanoma	1.18e-06	1.6e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—melanoma	1.18e-06	1.6e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CB—melanoma	1.18e-06	1.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—melanoma	1.18e-06	1.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1B—melanoma	1.17e-06	1.59e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—melanoma	1.17e-06	1.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—melanoma	1.15e-06	1.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—melanoma	1.15e-06	1.55e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—melanoma	1.12e-06	1.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—melanoma	1.12e-06	1.51e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CG—melanoma	1.11e-06	1.51e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—melanoma	1.11e-06	1.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—melanoma	1.11e-06	1.5e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—melanoma	1.11e-06	1.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—melanoma	1.09e-06	1.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—melanoma	1.09e-06	1.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—melanoma	1.09e-06	1.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—melanoma	1.08e-06	1.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—melanoma	1.08e-06	1.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFKB1—melanoma	1.07e-06	1.45e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—melanoma	1.07e-06	1.45e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PRKCA—melanoma	1.07e-06	1.45e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ERCC2—melanoma	1.06e-06	1.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—melanoma	1.04e-06	1.41e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP17A1—melanoma	1.03e-06	1.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—melanoma	1.03e-06	1.39e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—melanoma	1.02e-06	1.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—melanoma	1.01e-06	1.36e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—melanoma	9.92e-07	1.34e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CD—melanoma	9.78e-07	1.32e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNA11—melanoma	9.77e-07	1.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—melanoma	9.75e-07	1.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—melanoma	9.65e-07	1.31e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—melanoma	9.65e-07	1.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—melanoma	9.63e-07	1.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—melanoma	9.63e-07	1.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—melanoma	9.62e-07	1.3e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FASN—melanoma	9.56e-07	1.3e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—melanoma	9.49e-07	1.29e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC5A5—melanoma	9.41e-07	1.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK3—melanoma	9.22e-07	1.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—melanoma	9.08e-07	1.23e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNAQ—melanoma	9.08e-07	1.23e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CD44—melanoma	9.08e-07	1.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—melanoma	8.97e-07	1.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—melanoma	8.88e-07	1.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK1—melanoma	8.77e-07	1.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—melanoma	8.77e-07	1.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1B1—melanoma	8.71e-07	1.18e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CB—melanoma	8.52e-07	1.15e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—melanoma	8.44e-07	1.14e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CG—melanoma	8.39e-07	1.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—melanoma	8.38e-07	1.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—melanoma	8.29e-07	1.12e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—melanoma	8.1e-07	1.1e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—melanoma	7.83e-07	1.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—melanoma	7.61e-07	1.03e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CD—melanoma	7.38e-07	9.99e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—melanoma	7.37e-07	9.97e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—melanoma	7.36e-07	9.97e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—melanoma	7.28e-07	9.86e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—melanoma	7.19e-07	9.73e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—melanoma	7.17e-07	9.71e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—melanoma	7.04e-07	9.54e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—melanoma	6.74e-07	9.13e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PRKCA—melanoma	6.6e-07	8.94e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ERCC2—melanoma	6.55e-07	8.87e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CB—melanoma	6.43e-07	8.71e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—melanoma	6.4e-07	8.66e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—melanoma	6.37e-07	8.63e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—melanoma	6.22e-07	8.42e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—melanoma	5.87e-07	7.95e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—melanoma	5.56e-07	7.53e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—melanoma	5.19e-07	7.04e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CG—melanoma	5.17e-07	7e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—melanoma	4.99e-07	6.76e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CD—melanoma	4.54e-07	6.16e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—melanoma	4.49e-07	6.08e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—melanoma	4.24e-07	5.75e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CB—melanoma	3.96e-07	5.37e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—melanoma	3.93e-07	5.32e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—melanoma	3.92e-07	5.31e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—melanoma	3.42e-07	4.64e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—melanoma	3.2e-07	4.34e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—melanoma	2.41e-07	3.27e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—melanoma	1.97e-07	2.67e-06	CbGpPWpGaD
